U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H18O3
Molecular Weight 282.3337
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ERTEBEREL

SMILES

OC1=CC=C(C=C1)[C@@H]2OC3=C(C=C(O)C=C3)[C@@H]4CCC[C@H]24

InChI

InChIKey=XIESSJVMWNJCGZ-VKJFTORMSA-N
InChI=1S/C18H18O3/c19-12-6-4-11(5-7-12)18-15-3-1-2-14(15)16-10-13(20)8-9-17(16)21-18/h4-10,14-15,18-20H,1-3H2/t14-,15+,18+/m1/s1

HIDE SMILES / InChI
Molecular Formula C18H18O3
Molecular Weight 282.3337
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800031986 | https://www.ncbi.nlm.nih.gov/pubmed/27126081

Synthetic compound Erteberel (LY500307) is a highly potent and selective ERβ agonist; it has a 12-fold higher affinity for ERβ than ERα and exhibits 32-fold more functional potency. LY500307 was well tolerated in benign prostatic hypertrophy (BPH) patients with no side effects and it is currently being tested in phase 2 clinical trials for improving negative symptoms and cognitive impairment associated with Schizophrenia. In BPH clinical trial incidence of adverse events was comparable between treatment groups, and no clinically meaningful changes in laboratory tests were observed.

CNS Activity

Originator

Eli Lilly
239
Curator's Comment: https://www.giiresearch.com/report/labd240920-eli-lilly-company-product-pipeline-review.html # Eli Lilly

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 0.19 nM [Ki]
Agonist
2752
 2.68 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
24.8 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/27136911
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERTEBEREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.18 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/27136911
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERTEBEREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
206 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/27136911
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERTEBEREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
24 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/27136911
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERTEBEREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
17.1 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/27136911
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERTEBEREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
15.7 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/27136911
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERTEBEREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P00DI6T
https://www.1pchem.com/search?query=1P00DI6T
AK Scientific
X7545
https://aksci.com/item_detail.php?cat=X7545
AstaTech
40678
http://astatechinc.com/CPSResult.php?CRNO=40678
Chem Scene
CS-0007402
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0007402
Debye Scientific
DA-33424
https://www.debyesci.com/index.php?id=product&ext[cno]=DA-33424
eMolecules
32278104
https://orderbb.emolecules.com/search/#?query=32278104
mcule
MCULE-8155191339
https://mcule.com/MCULE-8155191339/
mcule
MCULE-8334599085
https://mcule.com/MCULE-8334599085/
MedChem Express
HY-18295
https://www.medchemexpress.com/search.html?q=HY-18295&ft=&fa=&fp=
Molnova
M14897
https://www.molnova.com/en/serch-list.html?keywords=M14897
MolPort
MolPort-016-633-249
https://www.molport.com/shop/molecule-link/MolPort-016-633-249
MuseChem
I006706
https://www.musechem.com/product/I006706.html
Toronto Research Chemicals
E649895
https://www.trc-canada.com/product-detail/?CatNum=E649895
Toronto Research Chemicals
P839035
https://www.trc-canada.com/product-detail/?CatNum=P839035
PubMed

PubMed

TitleDatePubMed
Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.
2016-04-29
Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy.
2015-03
Fertility and developmental toxicity assessment in rats and rabbits with LY500307, a selective estrogen receptor beta (ERβ) agonist.
2013-10
Patents

Patents

20040249167
1
20070106082
1
20080312312
1
20090298925
1
7442812
1
7585985
1
7842822
1

Sample Use Guides

In Vivo Use Guide
1, 3, 10 and 25 mg once daily for 24 weeks
Route of Administration: Oral
In Vitro Use Guide
LY500307 (5 uM during 24 h) treatment significantly increased the percentage of cells in G2/M phase in U87, U251, LN229 and GBM10 cells when compared to vehicle.
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:20:54 GMT 2025
Edited
by admin
on Mon Mar 31 19:20:54 GMT 2025
Record UNII
2ZUL6758TZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
erteberel [INN]
Preferred Name English
ERTEBEREL
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
ERTEBEREL [USAN]
Common Name English
(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA(C)(1)BENZOPYRAN-8-OL
Common Name English
LY500307
Code English
CYCLOPENTA(C)(1)BENZOPYRAN-8-OL, 1,2,3,3A,4,9B-HEXAHYDRO-4-(4-HYDROXYPHENYL)-, (3AS,4R,9BR)-
Common Name English
LY-500307
Code English
SERBA-1
Common Name English
Erteberel [WHO-DD]
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID70201547
Created by admin on Mon Mar 31 19:20:54 GMT 2025 , Edited by admin on Mon Mar 31 19:20:54 GMT 2025
PRIMARY
WIKIPEDIA
Erteberel
Created by admin on Mon Mar 31 19:20:54 GMT 2025 , Edited by admin on Mon Mar 31 19:20:54 GMT 2025
PRIMARY
USAN
XX-46
Created by admin on Mon Mar 31 19:20:54 GMT 2025 , Edited by admin on Mon Mar 31 19:20:54 GMT 2025
PRIMARY
NCI_THESAURUS
C166610
Created by admin on Mon Mar 31 19:20:54 GMT 2025 , Edited by admin on Mon Mar 31 19:20:54 GMT 2025
PRIMARY
SMS_ID
300000034215
Created by admin on Mon Mar 31 19:20:54 GMT 2025 , Edited by admin on Mon Mar 31 19:20:54 GMT 2025
PRIMARY
DRUG BANK
DB07933
Created by admin on Mon Mar 31 19:20:54 GMT 2025 , Edited by admin on Mon Mar 31 19:20:54 GMT 2025
PRIMARY
FDA UNII
2ZUL6758TZ
Created by admin on Mon Mar 31 19:20:54 GMT 2025 , Edited by admin on Mon Mar 31 19:20:54 GMT 2025
PRIMARY
INN
9363
Created by admin on Mon Mar 31 19:20:54 GMT 2025 , Edited by admin on Mon Mar 31 19:20:54 GMT 2025
PRIMARY
CAS
533884-09-2
Created by admin on Mon Mar 31 19:20:54 GMT 2025 , Edited by admin on Mon Mar 31 19:20:54 GMT 2025
PRIMARY
PUBCHEM
10286159
Created by admin on Mon Mar 31 19:20:54 GMT 2025 , Edited by admin on Mon Mar 31 19:20:54 GMT 2025
PRIMARY
ChEMBL
CHEMBL278703
Created by admin on Mon Mar 31 19:20:54 GMT 2025 , Edited by admin on Mon Mar 31 19:20:54 GMT 2025
PRIMARY
Related Record Type Details
ESTROGEN RECEPTOR BETA
TARGET -> AGONIST
Related Record Type Details
Structure of ERTEBEREL
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966